IN8bio, Inc. INAB
0.87 USD +0.05 (+5.56%)
As ofNov 16, 2026, 2:18 PM EST
0.7236 Day range 0.9238
0.7236 52-week range 2.73
- YTD
- -63.01%
- 1 year
- -45.56%
News
benzinga.com IN8bio Presents Updated Clinical Data From INB-200 And INB-400 Programs In Newly Diagnosed GBM, In Oral Session At 2026 SNO Annual Meeting Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC)50% of repeat-dose patients remained alive at two…
globenewswire.com IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell
